TY  - GEN 
AU  - Angulo, J.C.
AU  - Ciria Santos, J.P.
AU  - Gómez Caamaño, Antonio
AU  - Poza de Celis, R.
AU  - González Sala, J.L.
AU  - García Garzón, J.M.
AU  - Galán-Llopis, J.A.
AU  - Pérez Sampietro, M.
AU  - Perrot, V.
AU  - Planas Morin, J.
AU  - Abascal, J.M.
AU  - Barrond, V.
AU  - Benedicto, A.
AU  - Carballo Castro, Ana María
AU  - Cortiñas, J.R.
AU  - Fernández, M.
AU  - Ferrer, E.
AU  - Guzmán, P.L.
AU  - López, M.Á.
AU  - Martínez, J.C.
AU  - Olivier, C.
AU  - Peleteiro Higuero, Paula
AU  - Pérez, P.J.
AU  - Pesqueira, D.
AU  - Ponce, J.
AU  - Ruibal, M.
AU  - Segarra, J.
AU  - Solsona, E.
AU  - Suárez, J.F.
AU  - Rosa, J.
AU  - Tabernero, Á.
AU  - Vesga, F.
AU  - Zapatero, A.
PY  - 2022
SN  - 1433-8726
UR  - http://hdl.handle.net/20.500.11940/20648
AB  - Purpose: Evaluate the percentage of patients with prostate cancer treated with luteinizing hormone-releasing hormone analogues (LHRHa) that develop castration resistance after a follow-up period of 3 years. The secondary objective is to evaluate the...
LA  - eng
TI  - Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
DO  - 10.1007/s00345-022-04108-x
KW  - CHUS
KW  - AS Santiago
KW  - IDIS
VL  - 40
ER  -